Tagraxofusp-erzs and Vinorelbine Tartrate

• Generic Name: tagraxofusp
• Dosage Forms: n.a.
• Other Brand Names: Elzonris

Tagraxofusp-erzs is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years of age and older.

• Generic Name: vinorelbine
• Dosage Forms: n.a.
• Other Brand Names: Navelbine

Used alone or in combination with cisplatin as first-line therapy in ambulatory patients for the palliative treatment of unresectable, advanced non-small cell lung cancer (NSCLC).

Used alone or in combination with cisplatin in patients with Stage IV NSCLC.

Use in combination with cisplatin is preferred treatment of advanced NSCLC in patients with good performance status because of improved response and survival.

Used in combination with cisplatin in patients with Stage III NSCLC.

Use in combination with cisplatin is being investigated for adjuvant treatment of completely resected NSCLC.

Use in combination with trastuzumab is being investigated for the treatment of HER2-overexpressing metastatic breast cancer.

Has been used as first-line or salvage therapy for metastatic breast cancer in combination with various other agents, including anthracyclines (e.g., doxorubicin), fluoropyrimidines (e.g., fluorouracil, capecitabine), mitoxantrone, cisplatin, taxanes (e.g., docetaxel, paclitaxel), ifosfamide, or gemcitabine.

Has been used as monotherapy in first-line or salvage (e.g., second-line or subsequent) treatment of metastatic breast cancer.

Use in the treatment of metastatic or recurrent cervical cancer is being investigated.

Use in combination with other antineoplastic agents (e.g., cisplatin) is being evaluated in patients with metastatic or recurrent cervical cancer.

Has been used in the treatment of adult soft tissue sarcomas.

Has been used in the treatment of esophageal cancer.